Emily Ankrom, PA
Physician Assistant · Dayton, OHNPI 1962803890
Payments from drug & device makers
Across 1,138 payments — averaging $168.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$94K
- Lilly USA, LLC$31K
- Takeda Pharmaceuticals U.S.A., Inc.$30K
- Johnson & Johnson$26K
- Pfizer$3K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $7K from 29 others
What the payments were for
- Consulting fees$8,0634%
- Speaking & faculty fees$140,58773%
- Travel & lodging$23,41912%
- Food & beverage$19,54210%
- Education$1610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 362 | $93,810 |
| Lilly USA, LLC | 87 | $30,791 |
| Takeda Pharmaceuticals U.S.A., Inc. | 155 | $29,586 |
| Johnson & Johnson | 151 | $25,866 |
| Pfizer | 90 | $3,162 |
| E.r. Squibb & Sons, L.L.C. | 4 | $2,009 |
| Janssen Scientific Affairs, LLC | 1 | $1,313 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 105 | $1,287 |
| Bristol Myers Squibb | 31 | $1,136 |
| Sanofi | 20 | $509 |
| QOL Medical, LLC | 17 | $312 |
| Celltrion USA Inc. | 9 | $207 |
| Daiichi Sankyo Inc. | 11 | $190 |
| Braintree Laboratories, Inc. | 7 | $170 |
| Ardelyx, Inc. | 9 | $162 |
| Ironwood Pharmaceuticals, Inc | 12 | $158 |
| Redhill Biopharma Inc. | 8 | $149 |
| Organon | 8 | $116 |
| Regeneron Healthcare Solutions, Inc. | 4 | $111 |
| Gilead | 7 | $104 |
| Merck | 7 | $93 |
| Nestle Healthcare Nutrition Inc. | 5 | $86 |
| Ferring Pharmaceuticals Inc. | 4 | $61 |
| Ipsen Biopharmaceuticals, Inc | 3 | $56 |
| Intercept Pharmaceuticals, Inc. | 4 | $53 |
| Aimmune Therapeutics, Inc. | 3 | $49 |
| Amgen | 3 | $47 |
| Evoke Pharma, Inc. | 3 | $42 |
| Boehringer Ingelheim | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Novo Nordisk | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Mylan Institutional Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$191,773 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 47 | $1,291,493 |
| Skyrizi On-BodyRisankizumab-Rzaa | 34 | $750,272 |
| RinvoqUpadacitinib | 26 | $261,863 |
| Humira(Cf) PenAdalimumab | 26 | $199,012 |
| EntyvioVedolizumab | 21 | $182,265 |
| SkyriziRisankizumab-Rzaa | 12 | $118,478 |
| XifaxanRifaximin | 25 | $64,526 |
| RezdiffraResmetirom | 14 | $57,440 |
| CreonLipase/Protease/Amylase | 11 | $43,332 |
| InflectraInfliximab-Dyyb | 11 | $40,992 |
| Mesalamine | 32 | $33,136 |
| Mesalamine ErMesalamine | 24 | $7,057 |
| Pantoprazole Sodium | 71 | $3,570 |
| Balsalazide Disodium | 11 | $3,120 |
| Cholestyramine LightCholestyramine | 23 | $3,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $25,866 | $1,291,49347 claims |
| AbbVieRinvoq, Skyrizi, Creon | $93,810 | $423,67349 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $29,586 | $182,26521 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,287 | $64,52625 claims |
| PfizerInflectra | $3,162 | $40,99211 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $21 | $5214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.
Other physician assistant in Dayton
- Mackenzie TideringtonDayton$20K
- Srikanth VangapanduDayton$17K
- Steven WurzelbacherCincinnati$309K
- Amanda MaggartWorthington$164K
- Megan SevillaMayfield Heights$132K
- Erin StrculaBelpre$106K
- Natalie WalkupSylvania$105K
- Sarah LaubNew Albany$100K
- Jessica RhominskiCanal Winchester$78K
- Alan OdonnellCincinnati$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.